Neuren Pharmaceuticals Limited
NURPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,599,277 | $3,166,553 | $1,006,840 | $452,022 |
| - Cash | $3,153 | $17,094 | $40,180 | $36,783 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1,596,124 | $3,149,459 | $966,660 | $415,239 |
| Revenue | $216,832 | $231,925 | $14,553 | $3,197 |
| % Growth | -6.5% | 1,493.7% | 355.2% | – |
| Gross Profit | $183,862 | $205,174 | $14,543 | $3,189 |
| % Margin | 84.8% | 88.5% | 99.9% | 99.7% |
| EBITDA | $179,183 | $199,262 | -$722 | -$8,225 |
| % Margin | 82.6% | 85.9% | -5% | -257.3% |
| Net Income | $142,043 | $157,081 | $184 | -$7,794 |
| % Margin | 65.5% | 67.7% | 1.3% | -243.8% |
| EPS Diluted | 1.09 | 1.2 | 0.001 | -0.066 |
| % Growth | -9.2% | 85,614.3% | 102.1% | – |
| Operating Cash Flow | -$11,270 | $184,925 | $3,599 | -$9,970 |
| Capital Expenditures | -$10 | -$40 | -$19 | -$10 |
| Free Cash Flow | -$11,280 | $184,885 | $3,580 | -$9,980 |